Anemia | Rami Komrokji, MD

Research To Practice | Oncology Videos

Novel and Emerging Therapeutic Strategies in the Management of Hematologic Disorder-Related Anemia — Part 1: Our interview with Dr Komrokji highlights the following topics and cases from his practice.

• Approved and emerging therapies for patients with transfusion-dependent myelodysplastic syndromes (MDS); mechanism of action of the investigational erythroid maturation agent (EMA) luspatercept (00:00)
• Design, entry criteria and outcomes of the Phase III MEDALIST trial of luspatercept for the treatment of anemia in patients with very low-, low- or intermediate-risk MDS with ring sideroblasts who require red blood cell (RBC) transfusions (2:10)
• Clinical experience with the EMAs luspatercept and sotatercept (6:03)
• Potential FDA approval of luspatercept for the management of low-risk MDS (9:11)
• Ongoing investigation of luspatercept-based strategies for MDS (12:25)
• Investigation of venetoclax in combination with a hypomethylating agent for higher-risk MDS (16:00)
• Role of luspatercept in myelofibrosis; predictors of benefit from luspatercept (18:24)
• Case: A man in his mid-70s presents with fatigue and dyspnea and is diagnosed with lower-risk MDS with ring sideroblasts (21:17)
• Initial workup and diagnosis for patients with MDS (23:58)
• Risk stratification in MDS and therapeutic options for patients at lower versus higher risk (25:52)
• Clinical experience with EMAs for lower-risk, RBC transfusion-dependent MDS (29:42)
• Monitoring and management of iron overload in patients with lower-risk, RBC transfusion-dependent MDS (32:30)
• Case: A man in his early 60s with lenalidomide-refractory, lower-risk MDS and a del(5q) mutation receives the telomerase inhibitor imetelstat on a clinical trial (36:09)
• Case: A man in his mid-70s with postpolycythemia vera myelofibrosis with anemia and splenomegaly receives initial ruxolitinib therapy (40:49)
• Activity and tolerability of JAK1/2 inhibitors in myelofibrosis (45:09)
• Case: A woman in her mid-70s with myelofibrosis and a JAK2 mutation presents with progressive splenomegaly and anemia and receives ruxolitinib (48:31)
• Novel agents and strategies under investigation for myeloproliferative neoplasms (MPNs) (50:40)
• Incidence of IDH1/2 mutations in patients with MPNs; responses to IDH1/2 inhibitors and ongoing clinical investigations (53:13)
• Activity of the antifibrotic immunomodulator PRM-151 in patients with myelofibrosis (56:04)
• Common misconceptions about the use of erythropoietin-stimulating agents (57:45)
• Perspective on the appropriate choice of therapy for patients with intermediate-2 or high-risk myelofibrosis (1:01:41)
• Lack of correlation between JAK2 mutation status and response to ruxolitinib (1:03:19)

Select publications